MoonLake Immunotherapeutics
MLTX
$54.39
-$0.49-0.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -221.44% | -256.99% | -230.31% | -76.82% | -18.21% |
| Total Depreciation and Amortization | 137.38% | 195.51% | 441.13% | 7,952.27% | 7,731.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.31% | 437.32% | 546.95% | 279.12% | 1,006.49% |
| Change in Net Operating Assets | 120.74% | 86.37% | 39.16% | -390.24% | -444.49% |
| Cash from Operations | -158.28% | -187.01% | -172.54% | -91.43% | -52.94% |
| Capital Expenditure | 30.97% | 30.97% | -82.64% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 132.15% | -64.35% | -723.61% | 144.82% | -- |
| Cash from Investing | 131.86% | -63.70% | -716.36% | 144.35% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.59% | -99.94% | -89.06% | -81.43% | -81.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 102.13% | 102.13% | 46.59% | -- | -- |
| Cash from Financing | -7.48% | -86.16% | -89.30% | -82.37% | -82.41% |
| Foreign Exchange rate Adjustments | 1,319.86% | 77.08% | 269.19% | -56.24% | 224.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.29% | -145.77% | -165.77% | -79.24% | -138.87% |